KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Gross Profit (2016 - 2025)

Biogen has reported Gross Profit over the past 17 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly results put Gross Profit at $1.8 billion for Q4 2025, down 4.67% from a year ago — trailing twelve months through Dec 2025 was $7.5 billion (up 1.64% YoY), and the annual figure for FY2025 was $7.5 billion, up 1.64%.
  • Gross Profit for Q4 2025 was $1.8 billion at Biogen, down from $1.9 billion in the prior quarter.
  • Over the last five years, Gross Profit for BIIB hit a ceiling of $2.6 billion in Q4 2021 and a floor of $1.7 billion in Q1 2024.
  • Median Gross Profit over the past 5 years was $2.0 billion (2022), compared with a mean of $2.0 billion.
  • Peak annual rise in Gross Profit hit 8.8% in 2021, while the deepest fall reached 29.21% in 2021.
  • Biogen's Gross Profit stood at $2.6 billion in 2021, then decreased by 7.39% to $2.4 billion in 2022, then fell by 6.63% to $2.2 billion in 2023, then fell by 15.8% to $1.9 billion in 2024, then decreased by 4.67% to $1.8 billion in 2025.
  • The last three reported values for Gross Profit were $1.8 billion (Q4 2025), $1.9 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.